Key result
Review outlines evidence for glycaemic control and cardiometabolic risk reduction in South Asian populations.
Coronary heart disease (CHD) is currently the leading cause of death worldwide and together with diabetes, poses a serious health threat, particularly in the Indian Asian population. Risk factor management has evolved considerably with the continued emergence of new and thought-provoking evidence. The stream of laboratory- and population-based research findings as well as unresolved controversies may pose dilemmas and conflicting impulses in most clinicians, and even in our more well-informed patients. As results of the most recent clinical trials on glycaemic control for macrovascular risk reduction are woven into concrete clinical practice guidelines, this paper seeks to sort through unwieldy evidence, keeping these findings in perspective, to deliver a clearer message for the context of South Asia and cardio-metabolic risk management.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2010) conducted a review in Diabetes and coronary heart disease. Glycaemic control and cardio-metabolic risk management was evaluated on Macrovascular risk reduction. Glycaemic control and cardio-metabolic risk management evidence from clinical trials is reviewed for macrovascular risk reduction in South Asian populations; no quantitative data are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: